Manufacturing

CGTs offer hope for the future of treatments, but the costly manufacturing, slow turnaround time, and need for supplies hinder progress.

The author describes how to seize market opportunities while navigating the requirements of both drug therapies and delivery devices.

Several steps need be taken to achieve lights-out, fully automated operations.

Through a collaboration, Avantor and Cytovance Biologics will accelerate plasmid optimization and sourcing services for viral vectors and mRNA-based vaccines and therapeutics.

PCI Pharma Services is investing $100 million in manufacturing capabilities and capacity expansion to its Bedford, NH facility.

908 Devices and CPI have formed a collaboration to optimize cell culture media to allow for improved process control.

Societal CDMO has signed a three-year manufacturing and supply agreement with InfectoPharm for Ritalin LA in Europe.

MilliporeSigma’s ZooMAb antibodies have been recognized for their low environmental impact by My Green Lab.

Schott has announced the inauguration of its new high-end polymer prefillable syringe manufacturing facility in Mülheim, Germany.

In this episode of Drug Digest, Pharmaceutical Technology editors, Felicity Thomas and Feliza Mirasol, examine the topic of emerging therapies in more detail, covering subjects such as the challenges of scale, the potential benefits of drug delivery innovation, importance of early analytical studies, the evolution of the regulatory landscape, and differences between regional regulatory requirements.

The new company has been appointed as a channel partner for Ireland by TSI Inc., a particle counter manufacturer.

The two companies signed an exclusive collaboration agreement for the Aidaptus auto-injector.

The guide reviews unit operations and establishes equipment requirements for continuous manufacturing of oral solid dosage forms.

The “cloud lab” is a virtual laboratory setting that can enable scientists to more quickly advance research.

In this episode of the Drug Solutions Podcast, Feliza Mirasol, Pharmaceutical Technology’s science editor, discusses technologies enabling biologics and emerging therapies manufacturing and development with Barry Holtz, PhD, chief scientific officer of Phylloceuticals, and Professor Yaakov Nahmias, founder and chief scientific officer, Tissue Dynamics and founder and president, Future Meat Technologies.

It is vital to consider optimal cleaning and disinfection practices when operating a cleanroom.

Resolving operational bottlenecks makes mAb manufacturing more efficient.

Researchers demonstrated a new cell lysis method using a novel solution to improve viral vector production.

Digital maintenance solutions can help visualize the value and key activities provided by the equipment vendor from inception to utilization.

With the majority of large pharmaceutical manufacturers aiming for carbon neutrality by 2030, reusable packaging remains a largely untapped approach in achieving measurable ESG gains.

Recent trends in dissolution testing have led to increased use of data integrity solutions and more biorelevant testing techniques.

The Spheronizer from DIOSNA Dierks & Söhne is designed for the granulation and pelletizing of particles during the development of oral solid dosage forms.

Sepha’s EZ Blister+ is a compact small-batch blister packaging machine that is 21 CFR Part 11 compliant.

The KTEvolution from Tower Cold Chain is a lightweight, reusable container designed for the transport of pharmaceutical products.

ROSS incorporated a high shear rotor/stator into its Dual-Shaft Mixer to meet more intense shearing and homogenization requirements.

Societal CDMO has been awarded a new manufacturing and packaging task order agreement by National Cancer Institute.

Thermo Fisher Scientific has expanded its state-of-the-art R&D facility in Hyderabad, India.

FDA has approved commercial production at Kite’s new CAR T-cell therapy manufacturing facility in Frederick, Maryland.

Catalent will invest $350 million into integrated biologics drug substance and drug product manufacturing at Bloomington, Indiana facility.

The European Investment Bank has provided €15 million to fund coronavirus research at IRBM.